Yes, that's my understanding also. You are correct for sure, that the FDA decision was the pre-cursor to the big drop. I bought big prior to that decision and have seen 65% of my money burn - them's the breaks right - don't be in the kitchen if you cannot take the heat. As per your last line - I do see things differently.
Yet the sp has not recovered - market must remain in fear of the label change. Also the sp has not responded to the better sales numbers last quarter. Of course it did at first but most of the initial enthusiasm has now melted away.
So perhaps we can say the market is waiting to see if the last Q numbers are repeated or beaten. If it is the former you might see another burst of excitement but then I fully expect to revisit the low 70 cents again. If the numbers are beaten by a large amount we might be talking a larger move upwards - but what are the chances?
I think the company must focus on what it can control rather than Axiron numbers that are in the hands of consumers and Lilly.
Add to My Watchlist
What is My Watchlist?
